Optometrists in Fpo, AE Accepting Medicare
3 Optometrists found. Showing 1 - 3
 Dr. Alan Michael Cantrell, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: Psc 819 Box 18, Fpo, AE 09645 Phone: 195-682-3495 |
Dr. Robert N Kang, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: Psc 821 Box 14, Fpo, AE 09421 Phone: 441-638-52 |
Dr. Eric Harold Barnes, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: Psc 819 Box 18 #351, Fpo, AE 09645 Phone: 011-349-56823491 |
News Archive
MDI to advance Detect-Ready MRSA Panel with $1.9M Series B recapitalization financing
Molecular Detection Inc., a company developing Detect-Ready® tests designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has completed a $1.9 million Series B recapitalization financing.
Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency
Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.
Alcohol drinking pattern influences risk of cirrhosis
Approximately 170,000 people die from alcoholic cirrhosis of the liver in Europe every year. Although alcohol is the most important risk factor, less is known about the significance of different patterns of drinking. Currently scientists believe that cirrhosis is a function of the volume of alcohol consumed irrespective of patterns of drinking. Investigators have now established that alcohol drinking pattern has a significant influence on the risk of cirrhosis and that daily drinking increases that risk compared with drinking less frequently.
Alimera Sciences submits MAA for Iluvien to MHRA
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals has submitted a Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom for Iluvien (fluocinolone acetonide intravitreal insert).
Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).
› Verified 2 days ago
Physical Therapists
Speech-Language Pathologists
Optometrists
Occupational Therapists